Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | HRO761 + Tislelizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HRO761 | HRO-761|HRO 761 | HRO761 binds to and inhibits WRN, potentially resulting in antitumor activity (Ann Oncol (2023) 34 (suppl_2): S496). | ||
Tislelizumab | BGB-A317 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05838768 | Phase I | HRO761 HRO761 + Tislelizumab HRO761 + Irinotecan | Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | Recruiting | USA | FRA | ESP | DEU | BEL | 6 |